During the past decade, Azienda Ospedaliera San Camillo Forlanini conducted 124 clinical trials. In the 10-year time frame, 124 clinical trials started and 55 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 41 clinical trials started and 44 clinical trials were completed. i.e. 107.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Azienda Ospedaliera San Camillo Forlanini" #1 sponsor was "Hoffmann-La Roche" with 13 trials, followed by "Celgene" with 9 trials sponsored, "Pfizer" with 9 trials sponsored, "Takeda" with 8 trials sponsored and "Boehringer Ingelheim" with 8 trials sponsored. Other sponsors include 146 different institutions and companies that sponsored additional 101 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Azienda Ospedaliera San Camillo Forlanini" #1 collaborator was "Bristol-Myers Squibb" with 3 trials as a collaborator, "Clinical Research Technology S.r.l." with 3 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator and "Eli Lilly and Company" with 2 trials as a collaborator. Other collaborators include 94 different institutions and companies that were collaborators in the rest 100 trials.

According to Clinical.Site data, the most researched conditions in "Azienda Ospedaliera San Camillo Forlanini" are "Crohn's Disease" (12 trials), "Ulcerative Colitis" (10 trials), "Crohn Disease" (8 trials), "Non-Small Cell Lung Cancer" (7 trials) and "Prostate Cancer" (6 trials). Many other conditions were trialed in "Azienda Ospedaliera San Camillo Forlanini" in a lesser frequency.

Most popular intervention types in "Azienda Ospedaliera San Camillo Forlanini" are "Drug" (137 trials), "Other" (24 trials), "Procedure" (17 trials), "Device" (15 trials) and "Biological" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (39 trials), "Atezolizumab" (7 trials), "Carboplatin" (6 trials), "Docetaxel" (6 trials) and "Pembrolizumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "Azienda Ospedaliera San Camillo Forlanini" are 183 trials for "All" genders, 13 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Azienda Ospedaliera San Camillo Forlanini". undefined are not yet recruiting, 22 are recruiting, 35 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 105 completed trials in Azienda Ospedaliera San Camillo Forlanini, 1 suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Azienda Ospedaliera San Camillo Forlanini, 4 "Phase 1" clinical trials were conducted, 45 "Phase 2" clinical trials and 97 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 11 trials that are defined as “Not Applicable".

Azienda Ospedaliera San Camillo Forlanini has several departments that took part in Clinical trials: "Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1" - 9 trials, "Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica" - 7 trials, "Ospedale San Camillo - Uoc Cardiologia 1" - 4 trials, "Azienda Ospedaliera S. Camillo Forlanini, UOC per il governo clinico in Oncologia Medica" - 2 trials